Expected Moves

Evaluation of BPTH's clinical progress. Absent a Q2 lifeline, this window likely forces a definitive restructuring, clinical halt, or reverse split to maintain listing compliance.

Estimated Q3 2026 results. The market will heavily scrutinize the sheer share count post-dilution and any updates on continuing operations.

Estimated full year 2026 results and 10-K filing. Auditor opinions regarding BPTH's ability to continue as a going concern will be the primary catalyst.